Anya Lublinsky
Takeda (United States)(US)Education Development Center(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Ubiquitin and proteasome pathways, Toxin Mechanisms and Immunotoxins, Synthesis and Biological Evaluation, Cancer-related Molecular Pathways
Most-Cited Works
- → A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment(2018)441 cited
- → Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer(2021)197 cited
- → Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma(2019)14 cited
- → A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)(2019)7 cited
- → Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma(2024)3 cited
- → 561 Nonclinical characterization of the first in class investigational ubiquitin activating enzyme inhibitor MLN7243 in cellular and in vivo models of cancer in support of a phase I study(2014)1 cited
- → CCDC 2013738: Experimental Crystal Structure Determination(2021)
- Preclinical evaluation of MLN4924, the first small molecule inhibitor of NEDD8-activating enzyme (NAE) for the treatment of cancer(2007)
- → Abstract 5228: Engineering CD123-targeting vδ1-enriched γδT cells with enhanced preclinical efficacy and safety profile(2024)